genome sequenc- ing 1s being used to help people with relapsed cancers and who have run out of options. The project puts insights from stud- ies like Solit’s into practice, analyzing a patient’s tumor to determine whether currently available drugs might target the troublemaker mutations. Combining whole

d’ve been absurdly time-consuming and expen- sive. Now the sequencing takes as little as a few days. Poring over the outlier patient’s genetic code, Solit pinpointed two mutations that made her tumor sensi- tive to this drug. He found that one of her mutations shows up in about 8 to 10 percent of other